Sanofi Raises FY21 Earnings Outlook As Dupixent, Vaccines Boost Q3 Performance

  • Sanofi SA's SNY Q3 sales grew 10.1% Y/Y to €10.4 billion due to solid growth from Dupixent, Vaccines, and Consumer Healthcare.
  • EPS for the quarter increased 19.1% on reported and CER basis to €2.18.
  • Sales from eczema treatment, Dupixent, jumped 54% to €1.41 billion.
  • Vaccines sales increased 16.5% to €2.42 billion with record quarterly sales driven by flu vaccines and meningitis franchise recovery.
  • Consumer Healthcare sales increased 11.1% to €1.16 billion, driven by the growth of Pain care and Digestive Wellness categories.
  • The gross margin increased 1.9 percentage points to 72.8% versus the third quarter of 2020.
  • Sanofi generated a free cash flow of €2.20 billion.
  • Guidance: Sanofi now expects EPS to climb by around 14% at constant currencies for FY21, up from a previous, already improved estimate for 12% growth released in July.
  • Read Next: Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism.
  • Price Action: SNY shares traded higher by 0.69% at $49.91 premarket on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!